Trevi Therapeutics, Inc. - Common Stock, $0.001 par value (TRVI)

Historical Holders from Q2 2019 to Q1 2025

Symbol
TRVI on Nasdaq
CUSIP
89532M101
Type / Class
Equity / Common Stock, $0.001 par value
Shares outstanding
100M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
79.5M
Holdings value
$329M
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
107
Number of buys
67
Number of sells
-29
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value (TRVI)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
New Enterprise Associates 16, L.P. 15% $94.8M 15.1M New Enterprise Associates 16, L.P. Mar 18, 2025
Frazier Life Sciences Public Fund, L.P. 11.9% $67.1M 10.7M James N. Topper Dec 31, 2024
Rubric Capital Management LP 4.71% $26.5M 4.21M Rubric Capital Management LP Dec 31, 2024
Venrock Healthcare Capital Partners II, L.P. 1.4% $7.97M 1.27M Venrock Healthcare Capital Partners II, L.P. Dec 31, 2024
Rosalind Advisors, Inc. 1.2% $6.68M 1.06M Rosalind Advisors, Inc. Feb 13, 2025

Institutional Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value (TRVI)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 233K $1.46M +$66.5K $6.29 8
2024 Q4 79.5M $329M +$80.4M $4.12 107
2024 Q3 58.1M $194M +$7.24M $3.34 92
2024 Q2 55.9M $167M +$12.8M $2.98 77
2024 Q1 51.6M $178M -$5.42K $3.45 79
2023 Q4 49.8M $66.7M -$4.4M $1.34 60
2023 Q3 48.7M $106M -$321K $2.18 55
2023 Q2 48.8M $117M +$12.8M $2.39 53
2023 Q1 43.5M $80.4M +$499K $1.85 35
2022 Q4 43.2M $83.3M -$4.14M $1.93 36
2022 Q3 45.8M $70.5M +$26.2M $1.54 37
2022 Q2 28.8M $80.8M +$60.7M $2.81 31
2022 Q1 7.16M $15.8M +$2.08M $2.20 20
2021 Q4 13.1M $10.3M -$220K $0.78 14
2021 Q3 12.4M $17.4M -$64K $1.40 15
2021 Q2 12.5M $28.1M -$1.75M $2.25 15
2021 Q1 13.1M $35.6M +$339K $2.71 17
2020 Q4 13M $31.7M -$645K $2.42 17
2020 Q3 13.3M $53.5M -$728K $4.03 13
2020 Q2 13.4M $88M -$1.32M $6.58 12
2020 Q1 14M $45.9M -$780K $3.29 17
2019 Q4 14.2M $53.2M -$141K $3.75 15
2019 Q3 14.1M $63.5M -$268K $4.50 17
2019 Q2 14.2M $106M +$106M $7.50 18